• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

激活环酪氨酸磷酸化在 c-Kit 自身激活机制中的作用及其在舒尼替尼耐药中的意义。

Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.

机构信息

Pfizer Research Technology Center, 620 Memorial Drive, Cambridge, MA 02139, USA.

出版信息

J Biochem. 2010 Apr;147(4):601-9. doi: 10.1093/jb/mvq015. Epub 2010 Feb 10.

DOI:10.1093/jb/mvq015
PMID:20147452
Abstract

The activation of receptor tyrosine kinases (RTKs) is tightly regulated through a variety of mechanisms. Kinetic studies show that activation of c-Kit RTK occurs through an inter-molecular autophosphorylation. Phosphopeptide mapping of c-Kit reveals that 14-22 phosphates are added to each mol of wild-type (WT) c-Kit during the activation. Phosphorylation sites are found on the JM, kinase insert (KID), c-terminal domains and the activation loop (A-loop), but only the sites on the JM domain contribute to the kinase activation. The A-loop tyrosine (Y(823)) is not phosphorylated until very late in the activation (>90% completion), indicating that the A-loop phosphorylation is not required for c-Kit activation. A sunitinib-resistant mutant D816H that accelerates auto-activation by 184-fold shows no phosphorylation on the A-loop tyrosine after full activation. A loss-of-phosphorylation mutation Y823F remains fully competent in auto-activation. Similar to WT and D816H, the unactivated Y823F mutant binds sunitinib and imatinib with high affinity (K(D) = 5.9 nM). But unlike the WT and D816H where the activated enzymes lose the ability to bind the two drugs, activated Y823F binds the two inhibitors effectively. These observations suggest that the A-loop of activated Y823F remains flexible and can readily adopt unactivated conformations to accommodate DFG-out binders.

摘要

受体酪氨酸激酶 (RTKs) 的激活受到多种机制的严格调控。动力学研究表明,c-Kit RTK 的激活是通过分子间的自身磷酸化来实现的。对 c-Kit 的磷酸肽图谱分析表明,在激活过程中,每个 WT c-Kit 分子会添加 14-22 个磷酸。磷酸化位点位于 JM、激酶插入 (KID)、C 端结构域和激活环 (A 环) 上,但只有 JM 结构域上的位点对激酶的激活有贡献。A 环酪氨酸 (Y(823)) 在激活过程中很晚才被磷酸化(>90%完成),这表明 A 环磷酸化不是 c-Kit 激活所必需的。一个能使自身激活速度加快 184 倍的对舒尼替尼耐药的 D816H 突变体在完全激活后 A 环酪氨酸没有被磷酸化。一个失去磷酸化能力的 Y823F 突变体仍然完全有能力进行自身激活。与 WT 和 D816H 相似,未激活的 Y823F 突变体与舒尼替尼和伊马替尼具有高亲和力(K(D) = 5.9 nM)。但与 WT 和 D816H 不同的是,激活后的酶失去了与这两种药物结合的能力,而激活后的 Y823F 可以有效地结合这两种抑制剂。这些观察结果表明,激活的 Y823F 的 A 环仍然具有灵活性,可以很容易地采用非激活构象来容纳 DFG-out 结合物。

相似文献

1
Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.激活环酪氨酸磷酸化在 c-Kit 自身激活机制中的作用及其在舒尼替尼耐药中的意义。
J Biochem. 2010 Apr;147(4):601-9. doi: 10.1093/jb/mvq015. Epub 2010 Feb 10.
2
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.KIT激酶突变体在胃肠道间质瘤患者中显示出对伊马替尼和舒尼替尼独特的耐药机制。
Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7. doi: 10.1073/pnas.0812413106. Epub 2009 Jan 21.
3
Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry.氢氘交换傅立叶变换离子回旋共振质谱揭示 KIT 酪氨酸激酶的药物结合和耐药机制。
Protein Sci. 2010 Apr;19(4):703-15. doi: 10.1002/pro.347.
4
Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.突变 D816V 改变了 c-KIT 受体细胞质区域的内部结构和动力学:对二聚化和激活机制的影响。
PLoS Comput Biol. 2011 Jun;7(6):e1002068. doi: 10.1371/journal.pcbi.1002068. Epub 2011 Jun 16.
5
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.达沙替尼(BMS-354825),一种双重SRC/ABL激酶抑制剂,可抑制与人类恶性肿瘤相关的野生型、近膜区和激活环突变型KIT异构体的激酶活性。
Cancer Res. 2006 Jan 1;66(1):473-81. doi: 10.1158/0008-5472.CAN-05-2050.
6
Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit.酪氨酸激酶 cAbl 和 cKit 耐药的分子机制。
Crit Rev Biochem Mol Biol. 2011 Aug;46(4):295-309. doi: 10.3109/10409238.2011.578612. Epub 2011 May 4.
7
Phosphorylation in the activation loop as the finishing touch in c-Kit activation.磷酸化在激活环中作为 c-Kit 激活的点睛之笔。
J Biochem. 2012 May;151(5):457-9. doi: 10.1093/jb/mvs031. Epub 2012 Mar 20.
8
A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.KIT 活性状态和非活性状态之间的动态平衡转变导致了耐药性。
Proteins. 2020 Nov;88(11):1434-1446. doi: 10.1002/prot.25963. Epub 2020 Jun 25.
9
The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.小分子 Kit 蛋白酪氨酸激酶抑制剂在肿瘤疾病治疗中的作用。
Pharmacol Res. 2018 Jul;133:35-52. doi: 10.1016/j.phrs.2018.04.020. Epub 2018 Apr 25.
10
Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.酪氨酸激酶抑制剂STI571和AG1296可选择性抑制由近膜结构域而非催化结构域突变导致的c-kit组成型激活。
Int J Hematol. 2002 Dec;76(5):427-35. doi: 10.1007/BF02982808.

引用本文的文献

1
Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives.晚期胃肠道间质瘤(GISTs)的分子靶向治疗选择:当前实践与未来展望
Cancers (Basel). 2023 Mar 30;15(7):2074. doi: 10.3390/cancers15072074.
2
Does Generic Cyclic Kinase Insert Domain of Receptor Tyrosine Kinase KIT Clone Its Native Homologue?受体酪氨酸激酶 KIT 的通用环化酶插入结构域是否能复制其天然同源物?
Int J Mol Sci. 2022 Oct 25;23(21):12898. doi: 10.3390/ijms232112898.
3
Discovery of novel heteroaryl alkynes for highly potent KIT cells inhibition to treat gastrointestinal stromal tumors.
发现用于高效抑制KIT细胞以治疗胃肠道间质瘤的新型杂芳基炔烃。
Acta Pharm Sin B. 2022 Oct;12(10):4004-4007. doi: 10.1016/j.apsb.2022.07.015. Epub 2022 Aug 3.
4
Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations.通过自由能计算评估酪氨酸激酶 KIT 的激活。
J Chem Theory Comput. 2022 Oct 11;18(10):6251-6258. doi: 10.1021/acs.jctc.2c00526. Epub 2022 Sep 27.
5
The Inherent Coupling of Intrinsically Disordered Regions in the Multidomain Receptor Tyrosine Kinase KIT.多结构域受体酪氨酸激酶 KIT 中固有无序区域的固有偶联。
Int J Mol Sci. 2022 Jan 29;23(3):1589. doi: 10.3390/ijms23031589.
6
Role of EGF Receptor Regulatory Networks in the Host Response to Viral Infections.EGF 受体调控网络在宿主抗病毒感染反应中的作用。
Front Cell Infect Microbiol. 2022 Jan 10;11:820355. doi: 10.3389/fcimb.2021.820355. eCollection 2021.
7
Folding and Intrinsic Disorder of the Receptor Tyrosine Kinase KIT Insert Domain Seen by Conventional Molecular Dynamics Simulations.通过传统分子动力学模拟观察到受体酪氨酸激酶 KIT 插入结构域的折叠和固有无序。
Int J Mol Sci. 2021 Jul 9;22(14):7375. doi: 10.3390/ijms22147375.
8
Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats.小檗碱可预防应激引起的肠道炎症和内脏敏化,并降低大鼠的肠道蠕动。
World J Gastroenterol. 2019 Aug 7;25(29):3956-3971. doi: 10.3748/wjg.v25.i29.3956.
9
A threshold model for receptor tyrosine kinase signaling specificity and cell fate determination.一种用于受体酪氨酸激酶信号特异性和细胞命运决定的阈值模型。
F1000Res. 2018 Jun 21;7. doi: 10.12688/f1000research.14143.1. eCollection 2018.
10
Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome.干细胞生长因子/c-Kit在肠易激综合征发病机制中的作用
Exp Ther Med. 2017 Apr;13(4):1187-1193. doi: 10.3892/etm.2017.4133. Epub 2017 Feb 20.